People: Cornerstone Therapeutics Inc (CRTX.OQ)
CRTX.OQ on NASDAQ Stock Exchange Capital Market
8.51USD
1:06pm EDT
8.51USD
1:06pm EDT
Price Change (% chg)
$0.11 (+1.31%)
$0.11 (+1.31%)
Prev Close
$8.40
$8.40
Open
$8.33
$8.33
Day's High
$8.52
$8.52
Day's Low
$8.30
$8.30
Volume
5,148
5,148
Avg. Vol
19,648
19,648
52-wk High
$10.34
$10.34
52-wk Low
$3.10
$3.10
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Craig Collard |
47 | 2011 | Chairman of the Board, Chief Executive Officer |
Kenneth McBean |
47 | 2011 | President |
Alastair McEwan |
55 | 2012 | Chief Financial Officer, Principal Financial Officer, Treasurer |
Andrew Powell |
2009 | Executive Vice President, General Counsel, Secretary | |
Alan Roberts |
46 | 2009 | Vice President - Scientific Affairs |
Joshua Franklin |
2012 | Vice President - Strategy and Business Development | |
Anton Failla |
47 | 2009 | Director |
Laura Shawver |
52 | 2012 | Director |
Marco Vecchia |
52 | 2010 | Director |
Christopher Codeanne |
44 | 2008 | Independent Director |
Michael Enright |
50 | 2008 | Independent Director |
James Harper |
64 | 2011 | Independent Director |
Michael Heffernan |
48 | 2008 | Independent Director |
Robert Stephan |
69 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
Craig Collard |
Mr. Craig A. Collard is Chairman of the Board, Chief Executive Officer of Cornerstone Therapeutics Inc. In March 2004, Mr. Collard founded Cornerstone BioPharma Holdings, Ltd. (the assets and operations of which were restructured as Cornerstone BioPharma in May 2005), and served as its President and Chief Executive Officer and a director from March 2004 to October 2008. Before founding Cornerstone BioPharma, Mr. Collard’s principal occupation was serving as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company he founded in May 2003. From August 2002 to February 2003, Mr. Collard served as Vice President of Sales for Verum Pharmaceuticals, Inc., a specialty pharmaceutical company in Research Triangle Park, North Carolina. From 1998 to 2002, Mr. Collard worked as Director of National Accounts at DJ Pharma, Inc., a specialty pharmaceutical company which was eventually purchased by Biovail Pharmaceuticals, Inc., or Biovail. His pharmaceutical career began in 1992 as a field sales representative at Dura Pharmaceuticals, Inc., or Dura. He was later promoted to several other sales and marketing positions within Dura. Mr. Collard is a member of the Board of Directors of Hilltop Home Foundation, a Raleigh, North Carolina, non-profit corporation as well as the Triangle Chapter of the Cystic Fibrosis Foundation in addition to Board of Directors. Mr. Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University) in Marietta, Georgia. |
Kenneth McBean |
Mr. Kenneth McBean is President of Cornerstone Therapeutics Inc. Mr. McBean joins Cornerstone from Covidien plc, where he held the position of Vice President and General Manager of Specialty Pharmaceuticals from March 2009 until May 2011. At Covidien, Mr. McBean was responsible for executing a turnaround of the company's branded pharmaceutical products division. Prior to Covidien, Mr. McBean co-founded and headed commercial and corporate development for a number of Canadian-based pharmaceutical start-ups. In addition, he was formerly the Vice President of Marketing and Commercial Development for Biovail Pharmaceuticals and its predecessor company, DJ Pharma, in the US. His earlier career involved various US and global positions at Glaxo Wellcome and Marion Merrell Dow in commercial strategy, product management, market research, and sales. Mr. McBean holds a BS in Business from Kansas State University. |
Alastair McEwan |
Mr. Alastair S. McEwan is Chief Financial Officer, Principal Financial Officer, Treasurer of Cornerstone Therapeutics Inc. Mr. McEwan joined the Company from his role as a pharmaceutical industry consultant. In this role, from July 2006 to November 2012, Mr. McEwan consulted on various drug development initiatives and advised potential investors in numerous public and private mergers, acquisitions, divestments and capital restructuring initiatives. Mr. McEwan previously served on the Board following the completion of the Company’s merger with Cornerstone BioPharma Holdings, Inc. (“Cornerstone BioPharma”) on October 31, 2008 (whereby Cornerstone BioPharma became a wholly owned subsidiary of the Company) until July 28, 2009, the date of the completion of the original investment in the Company by Chiesi Farmaceutici S.p.A., the Company’s majority stockholder (the “Chiesi Transaction”). Mr. McEwan joined Cornerstone BioPharma’s board of directors in August 2005 and became chairman of its board of directors in January 2006, serving in such capacities until the completion of the Chiesi Transaction. From October 2005 through December 2005, Mr. McEwan served as Cornerstone BioPharma’s interim Chief Financial Officer. Prior to joining Cornerstone BioPharma, from June 1996 to December 2004, Mr. McEwan served in a variety of positions at Inveresk Research Group, Inc. (“Inveresk”), including as Group Executive Vice President, as President of Inveresk Global Clinical Operations and President of Inveresk Clinical Americas’ operations. Mr. McEwan also served as a member of the Group Executive Board of Inveresk from 1999 to 2004. Mr. McEwan served as director of Averion International Corp., a publicly traded international contract research organization, from February 2006 until December 2009. Mr. McEwan qualified as a Chartered Accountant in 1979 with the Institute of Chartered Accountants of Scotland and holds a Bachelor of Commerce from the University of Edinburgh. |
Andrew Powell |
Mr. Andrew Kenneth William Powell, Esq., is Executive Vice President, General Counsel, Secretary of Cornerstone Therapeutics Inc. Mr. Powell has practiced law for more than 25 years. He began his career at the firm of Gibson, Dunn & Crutcher in 1985, before joining Baxter International, or Baxter. From 1989 to 2004 he held positions at Baxter of increasing responsibility, playing key roles in a series of transactions that established the company throughout Asia, and heading up the global law function at Baxter Bioscience. From September 2004 to June 2008 he was a in the management team that developed CollaGenex Pharmaceuticals into a publicly traded commercial company that was sold to Galderma Laboratories. From July 2008 until January 2009 he was Senior Vice President and General Counsel at ImClone Systems, Inc. where he managed the sale of that company to Eli Lilly & Co. Mr. Powell holds a B.A. from the University of North Carolina at Chapel Hill and a J.D. from Stanford Law School. |
Alan Roberts |
Mr. Alan T. Roberts is Vice President - Scientific Affairs of Cornerstone Therapeutics Inc. In December 2007, Mr. Roberts founded Tybeam Pharma Consulting, LLC, or Tybeam, and serves as its President. Prior to founding Tybeam, Mr. Roberts served as Senior Vice President and Chief Scientific Officer for Auriga Laboratories, Inc., or Auriga, from February 2006 to December 2007. In January 2006, Mr. Roberts was named Vice President, Global Manufacturing and Development. He had served as Vice President, Scientific Affairs for First Horizon Pharmaceutical Corporation, or First Horizon since January 2005. Prior to becoming Vice President, Mr. Roberts was First Horizon’s Director of Regulatory, Quality and Manufacturing from June 2000 to June 2002, and Senior Director, Regulatory and Technical Affairs through 2004. From June 1999 to February 2000, Mr. Roberts was Vice President, Research and Development for Mikart, Inc., a private pharmaceutical contract manufacturer. Prior positions with Mikart were Research and Development Manager and Director of Research and Development from July 1993 to June 1999. Additional experience also includes key management positions in regulatory and development with Solvay Pharmaceuticals, Inc. and the Medical University of South Carolina’s Pharmaceutical Development Center, respectively. Mr. Roberts holds a B.S. in Microbiology from Clemson University. |
Joshua Franklin |
Mr. Joshua B. Franklin is Vice President - Strategy and Business Development of Cornerstone Therapeutics, Inc. Previously he served as Vice President of Marketing since merger with Cornerstone BioPharma. Before joining Cornerstone, Mr. Franklin served in a variety of marketing positions at Ther-Rx Corporation (a subsidiary of K-V Pharmaceutical Company) from July 2003 to September 2008, including most recently as Vice President, Marketing. Prior to joining Ther-Rx Corporation, Mr. Franklin held various marketing roles with Biovail from January 2002 to July 2003 and the Ross Products Division of Abbott Laboratories from August 1999 to January 2002. Mr. Franklin is a U.S. Army veteran and holds a B.S. in Business Administration from Methodist University and M.H.A. and M.B.A. degrees from The Ohio State University. |
Anton Failla |
Dr. Anton Giorgio Failla is Director of Cornerstone Therapeutics Inc. Since July 2008, Dr. Failla has served as Head of Business Development of Chiesi. Prior to his employment at Chiesi, from 2004 to 2008, Dr. Failla served as the CFO of Sorin Group, a medical device company, based in Milan, Italy and as its Senior Vice President of Operations based in Denver, Colorado. From 2000 to 2004, Dr. Failla served as Vice President, Business Development and Strategic Planning at Novartis Consumer Health, or Novartis, at its Headquarters in Switzerland. Prior to Novartis, Dr. Failla held various positions in business development at Medtronic Inc., both in the U.S. and in Europe. Dr. Failla has served on the boards of directors of several private companies in Europe and the United States: Bellco S.r.l. (April 2004-January 2007), Sorin Biomedica Cardio S.r.l. (April 2004-April 2005), Biofin Holding International N.V. (July 2004 -June 2006), Ela Medical S.a.s. (April 2004-June 2006), Sorin Biomedica CRM S.r.l. (April 2007-July 2008), Sorin Group International S.A. (December 2005-June 2006), Casino’Municipale Campione d’Italia (August 2007-June 2009), and Phenomix Corporation Inc. (February 2010-September 2010). Dr. Failla holds a Master in Business Administration from SDA Bocconi and a doctorate in Electronic Engineering from Polytechnic of Turin. |
Laura Shawver |
Dr. Laura K. Shawver, Ph.D., has been appointed as Director of Cornerstone Therapeutics Inc., with effect from June 6, 2012. Dr. Shawver has more than 20 years of experience in the biotechnology and pharmaceutical industry. In 2011, she participated in the founding of Cleave Biosciences, Inc., a development stage company, and currently serves as Chief Executive Officer and Director. Previously, she was Entrepreneur in Residence for 5AM Ventures, an early stage venture capital firm focused on building next-generation life science companies, from October 2010 to August 2011. Prior to then, Dr. Shawver served as Chief Executive Officer and Director of Phenomix Corporation, a development stage company, from June 2002 to September 2010, and President of Sugen, Inc. (“Sugen”) from October 2000 to May 2002, after holding various positions there since 1992. Sugen was a publically traded company from 1994 – 1999 when it was acquired by Pharmacia and Upjohn Company, Inc. Dr. Shawver began her drug development career in 1989 at Triton Biosciences, Inc. (later Berlex Biosciences Inc.), which was acquired by Schering AG in 1990. She has operational, drug development and regulatory experience, and also has assisted a number of pharmaceutical companies with transition and integration activities following product licensing and acquisition transactions. Dr. Shawver has served on the boards of Antipodean Pharmaceuticals, Inc. and Anaphore, Inc., and she is the founder and a current director of The Clearity Foundation, a non-profit corporation. Dr. Shawver holds a Ph.D. in Pharmacology and a B.S. in Microbiology, both from the University of Iowa. |
Marco Vecchia |
Mr. Marco Vecchia is Director of Cornerstone Therapeutics, Inc. Since 1987, Mr. Vecchia has served as Head of Legal and Corporate Affairs at Chiesi. Mr. Vecchia holds a degree in law from the University of Parma. Mr. Vecchia has also served on the boards of directors of the following companies: Chiesi S.A., Belgium, since June 2010; Chiesi Pharmaceuticals Shanghai Co. Ltd. (Wfoe), China, since June 2008; Cheshire Healthcare Limited, England, since January 2003; Chiesi Limited, England, since May 1999; Chiesi Healthcare Limited, England, since May 1999; Chiesi S.A., France, since April 2002; Chiesi Hellas Pharmaceuticals S.A., Greece, since April 1998; Chiesi Int. H. B.V., Holland, since April 2008; Chiesi Pharmaceuticals B.V., Holland, since February 2007; Opocrin S.P.A., Italy, since November 2008; Opocrin S.r.l., Italy, since November 2008; Novadynamics Healthcare S.r.l., Italy, since May 2007; Chiesi Pharmaceuticals Pvt Limited, Pakistan, since November 2001; Chiesi España S.A., Spain, since April 2000; Chiesi Pharmaceuticals Inc., USA, since April 1992. |
Christopher Codeanne |
Mr. Christopher G. Codeanne is Independent Director of Cornerstone Therapeutics Inc. Since December 2010, Mr. Codeanne has served as the Executive Vice President, Finance, Chief Financial Officer and Director of Premier Research Group Limited, an international pharmaceutical and medical device services company. From April 2008 through November 2010, Mr. Codeanne served as Chief Operating Officer and Chief Financial Officer of Oncology Development Partners, LLC (d/b/a Oncopartners), a specialized international oncology contract research organization. During 2010, Mr. Codeanne also served as an advisor for private equity firm Warburg Pincus. From December 2006 through April 2008, Mr. Codeanne served as the Chief Financial Officer of Averion International Corp., or Averion, a publicly traded international contract research organization. Prior to Averion, from 2002 through July 2006, Mr. Codeanne was the Chief Financial Officer of SCIREX Corporation (which was acquired by Premier Research Group plc in 2006), or SCIREX, an international, full-service clinical research organization. From 1999 to 2002, Mr. Codeanne served as Director of Finance of SCIREX. Mr. Codeanne is a member of the American Institute of Certified Public Accountants. Mr. Codeanne holds a B.A. in Accounting from Fairfield University and an MBA from the University of Connecticut. |
Michael Enright |
Mr. Michael Enright is Independent Director of Cornerstone Therapeutics Inc. Since February 2011, Mr. Enright has served as the President of OckhamCRO, a division of Ockham Development Group Inc., or Ockham, a global contract research organization. Prior to becoming President of OckhamCRO, Mr. Enright had served as the Chief Financial Officer for Ockham since its merger with Atlantic Search Group, Inc., a staff augmentation and functional outsourcing services organization serving pharmaceutical companies and contract research organizations in the United States and India, where he held the same position since 1995. Prior to 1995, Mr. Enright held positions in employee benefits administration with Hauser Insurance Group and The Prudential Insurance Company, and in financial management with General Electric Company’s aerospace business group. Mr. Enright holds a B.A. in Finance from Villanova University and an MBA from the Kenan-Flagler School of Business of the University of North Carolina at Chapel Hill. |
James Harper |
Mr. James A. Harper is Independent Director of Cornerstone Therapeutics Inc. Mr. Harper has over 30 years of experience in the pharmaceutical and medical device industries. He has also served on multiple corporate and not-for-profit boards of directors. He is currently Chair of Phenomix Corporation (Chair December 2009-present and director July 2007-present), and an advisor to Nomura Phase4 Ventures (July 2007-present). Prior to his retirement, Mr. Harper held a number of management and senior executive positions at Eli Lilly (January 1974-April 2004), including Group Vice President of Global Marketing and Sales and Chief Marketing Officer (January 2001-April 2004), President of Diabetes and Growth Disorders Product Group (January 1994-January 2001), and President and CEO of Advanced Cardiovascular Systems, a Lilly subsidiary (December 1990-December 1992). In addition, Mr. Harper has served on the boards of directors of Anesiva, Inc. (May 2007-December 2008), Corcept Therapeutics (October 2004-May 2011), Inoveon Corporation (June 2002-April 2004) and Zymogenetics, Inc (July 2004-October 2010). On these boards, he served on various committees including compensation, governance, and audit committees. Mr. Harper was a member of the National Board of Directors of the American Diabetes Association (July 1993-June 1997), where he was a member of the Research Policy Committee (July 2000-June 2001) and Vice Chair of the Research Foundation Board (2003-2006). He also served on the National Osteoporosis Foundation Corporate Advisory Board (July 1995-June 1997). Mr. Harper is a member of the National Association of Corporate Directors (March 2006-present). A veteran Navy flight officer, he holds a B.A. in Biology from Vanderbilt University and an MBA in Marketing/Finance from The Wharton School. |
Michael Heffernan |
Mr. Michael Thomas Heffernan is Independent Director of Cornerstone Therapeutics Inc. Since 2002, Mr. Heffernan has served as President and Chief Executive Officer of Collegium Pharmaceutical, Inc., a specialty pharmaceutical company that develops and commercializes products to treat central nervous system, respiratory and skin-related disorders. From 1999 to 2001, Mr. Heffernan served as President and Chief Executive Officer of PhyMatrix Corp., an integrated health care services company. From 1995 to 1999, Mr. Heffernan served as President and Chief Executive Officer of Clinical Studies Ltd., a pharmaceutical clinical development company. From 1987 to 1994, Mr. Heffernan served in a variety of sales and marketing positions with Eli Lilly and Company, a pharmaceutical company. Mr. Heffernan has also served on the Board of Directors of TyRx Pharma, Inc. since 2002, the Board of Directors of PreCision Dermatology, Inc. since 2010 and the Board of Directors of Advanced Cell Technology, Inc. since April 2012. Mr. Heffernan holds a B.S. in Pharmacy from the University of Connecticut and is a Registered Pharmacist. |
Robert Stephan |
Mr. Robert M. Stephan is Independent Director of Cornerstone Therapeutics Inc. Mr. Stephan is an experienced business attorney currently in private practice in New Canaan, Connecticut. With over 40 years experience, Mr. Stephan concentrates his law practice on domestic and international business transactions and serves as chief counsel to small and mid-sized companies and local counsel to foreign companies with operations in the United States. Mr. Stephan has served as Vice President and Secretary since 1997 and as a director since April 2009, of Chiesi Pharmaceuticals Inc., USA, a subsidiary of Chiesi. Prior to opening his private practice in 1997 and after initial training with the Office of the General Counsel of the SEC in Washington D.C. and the law firm of Day, Berry & Howard in Hartford, Connecticut, Mr. Stephan embarked on a career as in-house counsel with publicly traded corporations. He served as Vice President and Group General Counsel for General Mills Inc; Vice President and Associate General Counsel for US Surgical Corporation; Vice President, General Counsel and Secretary for Erbamont N.V. (Montedison Group); and Vice President, General Counsel and Secretary for American Maize Products Corporation. Mr. Stephan has advised boards of directors on corporate governance matters and is a former member of the National Association of Corporate Directors. Mr. Stephan is a former Captain/Judge Advocate in the United States Marine Corps and an Assistant Attorney General for the State of Wisconsin. Mr. Stephan holds a Bachelor of Arts in economics and political science from Lawrence University and a Juris Doctor from the University of Wisconsin Law School. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Craig Collard |
1,103,500 |
Kenneth McBean |
833,577 |
Alastair McEwan |
-- |
Andrew Powell |
555,749 |
Alan Roberts |
420,804 |
Joshua Franklin |
1,121,310 |
Anton Failla |
-- |
Laura Shawver |
-- |
Marco Vecchia |
-- |
Christopher Codeanne |
-- |
Michael Enright |
-- |
James Harper |
-- |
Michael Heffernan |
-- |
Robert Stephan |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Craig Collard |
0 | 0 |
Kenneth McBean |
0 | 0 |
Alastair McEwan |
0 | 0 |
Andrew Powell |
0 | 0 |
Alan Roberts |
0 | 0 |
Joshua Franklin |
0 | 0 |
Anton Failla |
0 | 0 |
Laura Shawver |
0 | 0 |
Marco Vecchia |
0 | 0 |
Christopher Codeanne |
0 | 0 |
Michael Enright |
0 | 0 |
James Harper |
0 | 0 |
Michael Heffernan |
0 | 0 |
Robert Stephan |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
MAETZEL ANDREAS |
25,000 | $0.00 |
DUARTE IRA |
7,000 | $0.00 |
FRANKLIN JOSHUA B |
25,000 | $0.00 |
MCBEAN KENNETH R |
40,000 | $0.00 |
ROBERTS ALAN T |
18,375 | $0.00 |
POWELL ANDREW KENNETH WILLIAM |
21,375 | $0.00 |
COLLARD CRAIG A |
45,000 | $0.00 |
MCBEAN KENNETH R |
1,217 | $5.58 |
MCEWAN ALASTAIR STUART |
50,000 | $0.00 |
MCBEAN KENNETH R |
1,022 | $4.85 |
POWELL ANDREW KENNETH WILLIAM |
2,045 | $6.27 |
MCBEAN KENNETH R |
4,056 | $6.30 |
FRANKLIN JOSHUA B |
38,637 | $3.90 |
FRANKLIN JOSHUA B |
38,637 | $6.86 |
FRANKLIN JOSHUA B |
24,688 | $3.90 |
FRANKLIN JOSHUA B |
24,688 | $7.01 |
MORGUS VINCENT T |
847 | $7.22 |
MORGUS VINCENT T |
787 | $5.94 |
FRANKLIN JOSHUA B |
4,056 | $5.04 |
ROBERTS ALAN T |
5,678 | $5.04 |
COLLARD CRAIG A |
1,443,913 | $6.25 |
CHIESI FARMACEUTICI SPA |
1,443,913 | $6.25 |
CHIESI FARMACEUTICI SPA |
3,400 | $6.08 |
CHIESI FARMACEUTICI SPA |
3,400 | $5.99 |
CHIESI FARMACEUTICI SPA |
3,400 | $5.85 |

